-
OPKO Invests $2M in Cardiac Device Company
Wednesday, August 17, 2011 - 8:51am | 109OPKO Health, Inc. (NYSE: OPK) today announced that it has made an investment in Neovasc Inc. (TSXV: NVC) a medical technology company based in Vancouver, Canada. Neovasc is developing unique devices to treat cardiovascular diseases and is also a leading supplier of tissue components for the...
-
Allos Therapeutics Initiates Phase 3 Registration Trial of FOLOTYN in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen
Wednesday, August 17, 2011 - 8:04am | 145Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the enrollment of the first patient in a Phase 3 randomized clinical trial evaluating FOLOTYN in patients with previously undiagnosed peripheral T-cell lymphoma. This study is open to enroll newly diagnosed patients with PTCL who have...
-
Celsion Announces Publication of Clinical and Scientific Review of ThermoDox as Treatment for Primary Liver Cancer
Wednesday, August 17, 2011 - 8:03am | 95Celsion Corporation (NASDAQ: CLSN) announced today the publication of a clinical and scientific review of ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin, as a treatment for Hepatocellular Carcinoma in the August 2011 issue of Future Oncology. The...
-
Protalix BioTherapeutics Announces FDA Accepts for Review Complete Response Resubmission for Taliglucerase Alfa and Assigns PDUFA Date
Wednesday, August 17, 2011 - 7:48am | 160Protalix BioTherapeutics, Inc. (NYSE: PLX) announced today that the U.S. Food & Drug Administration (FDA) has accepted for review the resubmission of the taliglucerase alfa New Drug Application following the Company's receipt of a Complete Response Letter in February 2011. The FDA deemed the...
-
Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed - Indolent Lymphoma
Wednesday, August 17, 2011 - 7:02am | 74Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin's B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal...
-
Goldman Sachs Initiates Micromet At Neutral, $5 PT
Wednesday, August 17, 2011 - 6:14am | 24Goldman Sachs has initiated coverage on Micromet (NASDAQ: MITI) with a Neutral rating and $5 price target.
-
Regeneron Announces Review of Biologics License Application for EYLEA; Says Review Extended by 3 Months by FDA
Tuesday, August 16, 2011 - 5:12pm | 73Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has received notification from the U.S. Food and Drug Administration that the agency has extended its target date to complete the priority review of the EYLEA Biologics License Application for the treatment of neovascular age-...
-
UPDATE: Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
Tuesday, August 16, 2011 - 4:02pm | 354Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that results from two pivotal KRYSTEXXA® (pegloticase) Phase III clinical studies in patients with refractory chronic gout have been published in The Journal of the American Medical Association. The data demonstrated that treatment with...
-
Clinical Investigators to Present Data on Nymox BPH Drug at American Urological Association Meeting October 19
Tuesday, August 16, 2011 - 12:15pm | 72Nymox Pharmaceutical Corporation (Nasdaq: NYMX) today announced that new clinical trial data concerning the safety and efficacy of the Company's NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the North Central Section of the American Urological Association Meeting in Rancho...
-
Midday Gainers; Carbonite up 18% on Heavy Volume
Tuesday, August 16, 2011 - 12:06pm | 44Carbonite (NASDAQ: CARB) +18.51% on heavy volume. Peregrine Pharmaceuticals (NASDAQ: PPHM) +10.95% on heavy volume. Majesco Entertainment (NASDAQ: COOL) +12.31% on heavy volume
-
Marshall Edwards Screams Higher
Tuesday, August 16, 2011 - 10:32am | 115Shares of Marshall Edwards (NASDAQ: MSHL) are screaming higher this morning on word that its Investigational New Drug application for ME-143, the Company's lead NADH oxidase inhibitor, has been approved by the FDA. Currently, shares are higher by 52.90%, trading at $2.11. Shares of Novogen Limited...
-
Zacks Maintains Outperform on EpiCept
Tuesday, August 16, 2011 - 9:49am | 129Zacks is out with its report today on EpiCept (NASDAQ: EPCT), maintaining Outperform. In its report, Zacks writes, "The Company s lead cancer candidate Ceplene has been already approved in EU and Israel for the remission maintenance of AML and a pivotal trial is planned in the US. The Company s...
-
Morning Market Movers
Tuesday, August 16, 2011 - 9:47am | 119Marshall Edwards Inc (NASDAQ: MSHL) climbed 40.58% to $1.94 at 9:45 am. The US Food and Drug Administration (FDA) approved the company's Investigational New Drug (IND) application for ME-143. Pernix Therapeutics Holdings Inc (AMEX: PTX) shares advanced 36.64% to $8.95. PTX's net revenue surged...
-
UPDATE: Rodman & Renshaw Lowers PT on Inovio from $4 to $2
Tuesday, August 16, 2011 - 9:29am | 93Rodman & Renshaw has published a report on Inovio Pharmaceuticals (AMEX: INO), lowering the price target from $4 to $2. In the report, Rodman & Renshaw wrote, "Inovio recently reported data from a Phase 1 trial of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza...
-
UPDATE: MLV Raises PT on Aastrom Biosciences to $7.50
Tuesday, August 16, 2011 - 9:19am | 83MLV is out with its report today on Aastrom Biosciences (NASDAQ: ASTM), raising its PT to $7.50 from $5.50. In its report, MLV writes, "We have revised our model and project that Aastrom could become profitable in 2015 following the launch of ixmyelocel-T (assuming REVIVE produces positive results...